Share

    


In This Section

Home / News & Media / Oncology Newsfeed

Oncology Newsfeed

  • FDA approves nivolumab and relatlimab-rmbw for melanoma

    On March 18, 2022, the U.S. Food and Drug Administration (FDA) approved nivolumab and relatlimab-rmbw for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

    Read the FDA announcement.

    Read Bristol Myers Squibb's announcement.

    Posted 3/21/2022


  • FDA Approves FoundationOne®CDx in Non-Small Cell Lung Cancer

    On Thursday, March 17, 2022, the U.S. Food and Drug Administration (FDA) approved the FoundationOne®CDx to be used as a companion diagnostic to identify patients with non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) alterations and are appropriate for treatment with EGFR tyrosine kinase inhibitors that are approved by FDA for this indication.

    Read Foundation Medicine's announcement.

    Posted 3/17/2022


  • FDA Approves BRACAnalysis® CDx in Early-Stage Breast Cancer

    On March 11, 2022, the U.S. Food and Drug Administration (FDA) approved Myriad Genetics, Inc.'s BRACAnalysis® CDx test for use as a companion diagnostic to identify patients with germline BRCA-mutated (gRBCAm) human epidermal growth factor receptor 2 (HER2)-negative, high-risk, early-stage breast cancer who may benefit from Lynparza® (olaparib) (AstraZeneca).

    Read the Myriad Genetics, Inc. announcement.

    Posted 3/14/2022



  • FDA Approves Olaparib for High-Risk Early Breast Cancer

    On Friday, March 11, 2022, the U.S. Food and Drug Administration (FDA) approved olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative, high-risk, early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.

    Read the FDA announcement.

    Read AstraZeneca's announcement.

    Posted 3/14/2022


  • FDA Approves Nivolumab in Combination for Early-Stage NSCLC

    On Friday, March 4, 2022, the U.S. Food and Drug Administration approved nivolumab with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting.

    Read the FDA announcement.

    Read Bristol Myers Squibb's announcement.

    Posted 3/7/2022


  • FDA Approves Pacritinib for Myelofibrosis

    On Monday, February 28, 2022, the U.S. Food and Drug Administration (FDA) approved pacritinib for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.

    Read CTI Biopharma's announcement.

    Posted 3/1/2022



  • FDA Approves Ciltacabtagene Autoleucel for R/R Multiple Myeloma

    On Monday, February 28, 2022, the U.S. Food and Drug Administration (FDA) approved ciltacabtagene autoleucel for the treatment of adults with relapsed or refractory (R/R) multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory agent, and an anti-CD38 monoclonal antibody.

    Read Janssen's announcement.

    Posted 3/1/2022



  • ACS National Consortium Releases Recommendations to Increase Screening

    On February 16, 2022, the American Cancer Society's National Consortium for Cancer Screening and Care (ACS National Consortium) announced new cancer screening recommendations to accelerate recovery from the COVID-19 pandemic. These recommendations also look to improve the United States' ability to provide quality cancer screening and care for all.

    The nine consensus recommendations include themes on:

    • National partnerships
    • Coordinated messaging
    • Proven programs
    • Quality measures
    • Pandemic-related innovations
    • Public trust
    • Comprehensive preparedness plans
    • Transdisciplinary teamwork
    • Document and understand cancer disparities.

    Read the full list and details of the recommendations on the ACS website.



  • FDA Approves FoundationOne®CDx to Identify MSI-H Solid Tumors

    Foundation Medicine, Inc. announced that it received approval from the U.S. Food and Drug Administration (FDA) for the FoundationOne®CDx to be used as a companion diagnostic to identify patients with microsatellite instability high (MSI-H) status solid tumors who may be appropriate for treatment with Merck’s Keytruda® (pembrolizumab).

    Read the Foundation Medicine announcement.

    Posted 2/22/2022



  • Servier Announces New NDC Number for Ivosidenib

    Starting today, February 14, 2022, Tibsovo® (ivosidenib tablets) will use NDC number 72694-0617-6 for ordering. Though the product packing has changed, Servier ensures the product and ordering process remain the same.

    For more information, visit the Tibsovo website.

    Posted 2/14/2022